Form 4: LGND CLO Reardon's Stock Transaction

Ligand Pharmaceuticals' CLO and Secretary, Andrew Reardon, reported a disposition of 1,325 common shares for tax purposes.

Summary

• Andrew Reardon, Chief Legal Officer (CLO) and Secretary of Ligand Pharmaceuticals Inc. (LGND), reported a transaction involving the company's common stock.
• On August 10, 2025, 1,325 shares of common stock were disposed of at a price of $150.06 per share.
• This disposition represents shares withheld by Ligand Pharmaceuticals to cover tax liabilities arising from the settlement of restricted stock units.
• Following this transaction, Andrew Reardon beneficially owns 30,811 shares of Ligand Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: This Form 4 reports a routine, non-discretionary transaction where shares were withheld by the company to cover tax liabilities associated with the vesting of restricted stock units. Such transactions are common for executives and do not typically indicate a change in company performance or outlook, thus warranting a neutral sentiment.

Future Outlook

This filing is a routine insider transaction report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically a tax-related disposition of shares. It does not provide information relevant to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related transaction by an insider, not a discretionary sale indicating a change in confidence or company fundamentals.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Andrew Reardon, Form 4, insider transaction, stock disposition, restricted stock units, RSU, tax withholding, corporate officer